Navigation Links
Oncothyreon to present at the Rodman & Renshaw Annual Global Investment Conference
Date:5/12/2010

SEATTLE, May 12 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Rodman & Renshaw Annual Global Investment Conference taking place in London on May 16-18, 2010.

Dr. Kirkman will present at 10:15 a.m. British Summer Time (5:15 a.m. Eastern Daylight Time) on Tuesday, May 18 at the Grosvenor House Hotel. A live and archived webcast of the presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Oncothyreon reports full year and fourth quarter 2009 financial results
2. Oncothyreon reports first quarter 2010 financial results
3. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
4. Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement
5. Oncothyreons PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
6. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
7. Oncothyreon announces webcast of third quarter 2009 financial results conference call
8. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
9. Oncothyreon to present at Rodman Renshaw Global Healthcare Conference
10. Oncothyreon reports second quarter 2009 financial results
11. Oncothyreon announces closing of $15.0 million registered direct financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... States multicenter, prospective clinical study that demonstrates the accuracy of the FebriDx® ... identifying clinically significant acute bacterial and viral respiratory tract infections by testing ...
(Date:10/11/2017)... N.C. (PRWEB) , ... October 11, 2017 , ... ... ARCS® Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, ... ( ASTER Labs ), Inc. has been selected for membership in ARCS ...
(Date:10/11/2017)... BALTIMORE, Md. (PRWEB) , ... October 11, 2017 ... ... for digital pathology, announced today it will be hosting a Webinar titled, “Pathology ... of  Advanced Pathology Associates , on digital pathology adoption best practices and how ...
(Date:10/11/2017)... ... October 11, 2017 , ... A ... pregnancy rates in frozen and fresh in vitro fertilization (IVF) transfer ... age to IVF success. , After comparing the results from the fresh and ...
Breaking Biology Technology:
(Date:5/23/2017)... 23, 2017  Hunova, the first robotic gym for the rehabilitation and ... launched in Genoa, Italy . The first 30 robots ... the USA . The technology was developed and patented ... the IIT spin-off Movendo Technology thanks to a 10 million euro investment ... please click: ...
(Date:4/19/2017)... , April 19, 2017 ... its vendor landscape is marked by the presence of ... is however held by five major players - 3M ... these companies accounted for nearly 61% of the global ... leading companies in the global military biometrics market boast ...
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
Breaking Biology News(10 mins):